Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-22T17:33:21.758Z Has data issue: false hasContentIssue false
  • English
  • Français

French Drug Policy

Published online by Cambridge University Press:  10 March 2009

Lucien Steru  and
Pierre Simon
Lucien Steru
Affiliation:
I.T.E.M., France
Pierre Simon
Affiliation:
C.H.U. Pitié-Salpêtrière, France
Get access Rights & Permissions [Opens in a new window]

Extract

French drug policy is closely controlled by the government to achieve two main purposes: to ensure therapeutic efficacy and safety, and to control pricing. Manufacturers usually price new drugs at the amount the French Sécurité Sociale (Social Security) agrees to reimburse the consumer. The specific steps a new ethical drug must go through in order to be released on the French market, and the process of negotiation between the government and the manufacturer are discussed in this paper.

Type
Special Section: The Evaluation of Drugs: An International Perspective
Information
International Journal of Technology Assessment in Health Care , Volume 2 , Issue 4 , October 1986 , pp. 637 - 642
Copyright
Copyright © Cambridge University Press 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Juillet, Y., & Desarmenien, H.La réglementation de la mise sur le marché des produits médicamenteux. La revue du praticien, 1983, 33, 17–22.Google Scholar
2.Tisseyre-Berry, M., & Belaisch-Scemama, F.Economie du médicament. Paris: Masson, 1981.Google Scholar
3.Tisseyre-Berry, M., & Viala, G.Legislation et déontologie de l'industrie pharmaceutique. Paris: Masson, 1984.Google Scholar
4.Weintraub, M.The French drug approval process II: The clinical basis for negative decisions by the Commission for Authorization of Marketing a Medication. Journal of Clinical Pharmacology, 1985, 25, 156–63.CrossRefGoogle ScholarPubMed
5.Weintraub, M.The French drug approval process. Journal of Clinical Pharmacology, 1982, 22, 213–22.Google Scholar